Why dead cells matter as much as live ones
Every day, roughly 50–70 billion cells die by apoptosis in the average adult human body. That number is staggering, and it demands an equally efficient removal system. Efferocytosis — from the Latin effero, "to carry out or bury" — is the process by which phagocytes, principally macrophages and dendritic cells, recognise, engulf, and digest these apoptotic corpses before they can progress to secondary necrosis.
Secondary necrosis is the inflammatory catastrophe that follows failed clearance. When an apoptotic cell is not engulfed within a few hours, its plasma membrane loses integrity. The cell spills its intracellular contents into the surrounding tissue: mitochondrial DNA, HMGB1, S100 proteins, uric acid crystals, and ATP — collectively termed damage-associated molecular patterns, or DAMPs. These molecules activate pattern-recognition receptors on neighbouring immune cells, triggering NF-κB-dependent cytokine cascades that can sustain inflammation for days or weeks after the original apoptotic signal has passed. In tissues with high apoptotic burden — atherosclerotic plaques, inflamed joints, autoimmune target organs — impaired efferocytosis is not a side note but a central driver of disease chronicity.
Find-me signals: summoning the phagocyte
An apoptotic cell actively recruits phagocytes through a class of soluble mediators called "find-me" signals. These are released into the extracellular space during the early phases of apoptosis, before the cell loses membrane integrity, creating chemotactic gradients that direct macrophage migration toward the dying cell.
- Lysophosphatidylcholine (LPC): Generated by caspase-3-dependent activation of phospholipase A2, LPC is released as a potent monocyte/macrophage chemoattractant. Its receptor on phagocytes is G2A (GPR132), and the LPC–G2A axis has been confirmed in multiple in vivo models of inflammation resolution.
- Sphingosine-1-phosphate (S1P): Released by apoptotic cells, S1P acts through S1P receptors (S1PR1–5) to guide macrophage and dendritic cell migration, and it also modulates the inflammatory tone of responding cells.
- CX3CL1 (fractalkine): Surface-expressed on healthy cells but shed from apoptotic cells as a soluble chemoattractant for CX3CR1-positive macrophages.
- Nucleotides — ATP and UTP: Released through pannexin-1 channels activated by caspase-3/7-mediated cleavage, extracellular ATP and UTP act on P2Y2 purinergic receptors on macrophages to guide chemotaxis. ATP also recruits monocytes through P2X1 receptors.
The coordinated release of these signals ensures that phagocytes arrive at the apoptotic cell before, not after, it has lost membrane integrity. This timing is not incidental — it is essential to the anti-inflammatory character of efferocytosis.
Eat-me signals: molecular flags on the apoptotic surface
Once a phagocyte arrives, it must distinguish apoptotic cells from healthy neighbours. This discrimination depends on a set of surface changes that apoptotic cells actively impose on themselves, broadly called "eat-me" signals.
Phosphatidylserine externalisation
Phosphatidylserine (PS) is normally confined to the cytoplasmic (inner) leaflet of the plasma membrane by the continuous activity of flippases — ATP-dependent P4-ATPases such as ATP11A and ATP11C. During apoptosis, two enzymatic events break this asymmetry. The TMEM16F protein (also known as ANO6, anoctamin-6), a Ca²⁺-activated phospholipid scramblase, and the caspase-cleaved XKR4 and XKR8 proteins act as scramblases that randomise lipid topology, allowing PS to migrate to the outer leaflet. This externalised PS is the primary "eat-me" signal for the entire efferocytosis machinery. Cells lacking both TMEM16F and XKR activity fail to externalise PS and are cleared inefficiently, confirming causality.
Calreticulin exposure
Calreticulin (CRT) is an ER-resident chaperone that translocates to the outer plasma membrane surface during ER stress and certain forms of apoptosis. Surface CRT acts as a direct "eat-me" signal by interacting with LRP1/CD91 on phagocytes. The CRT→LRP1 interaction is particularly important in immunogenic cell death — the form of apoptosis induced by certain chemotherapeutic agents that generates adaptive anti-tumour immunity.
Thrombospondin-1 as a bridging opsonin
Thrombospondin-1 (TSP1) bridges apoptotic cells to phagocytes via its capacity to bind several eat-me signals simultaneously and present them to CD36 or αvβ3 integrin on macrophages.
TAM receptors: the molecular heart of efferocytosis
The most mechanistically illuminated pathway for PS recognition by phagocytes involves the TAM family of receptor tyrosine kinases: TYRO3, AXL, and MERTK. These receptors do not bind PS directly. Instead, they rely on soluble bridging proteins — Gas6 (growth arrest-specific protein 6) and Protein S (PROS1) — that simultaneously engage PS on the apoptotic cell and the TAM receptor on the macrophage. Both Gas6 and Protein S are vitamin K-dependent γ-carboxylated proteins; the γ-carboxylated Gla domain confers the PS-binding affinity.
The stoichiometry is elegant: Gas6 or Protein S bind PS via their Gla domain, and their C-terminal LG domain activates MERTK or AXL by receptor dimerisation. The downstream signalling cascade — TAM receptor → PI3K (class I, generating PIP3) → Akt → RAC1/CDC42 activation — drives Rho-GTPase-dependent cytoskeletal reorganisation. This actin remodelling produces the phagocytic cup: a membrane extension that wraps around the apoptotic target. Simultaneously, Akt phosphorylation promotes phagosome formation and subsequent fusion with lysosomes for degradation.
TAM signalling has an additional, critical output: it is strongly anti-inflammatory. Ligand-stimulated MERTK and AXL induce SOCS1 and SOCS3, which block JAK–STAT signalling downstream of inflammatory cytokine receptors. Successful efferocytosis also triggers the production of IL-10 and TGF-β1 — cytokines that actively suppress macrophage activation, dampen T-cell responses, and promote tissue repair. This anti-inflammatory output is not a passive consequence of cell removal; it is an actively programmed signal that the resolved cell corpse was processed in a controlled, sterile manner rather than by necrotic rupture.
TIM-1 and TIM-4: direct PS receptors
Not all PS recognition requires bridging proteins. TIM-1 (T-cell immunoglobulin and mucin domain 1, also HAVCR1) and TIM-4 are members of the TIM family that bind PS directly via their IgV domains. TIM-4 is expressed on tissue-resident macrophages and is particularly important for steady-state clearance in the thymus, peritoneum, and liver. Genetic deletion of TIM-4 in mice produces a lupus-like autoimmune phenotype characterised by accumulation of uncleared apoptotic debris and autoantibody production — directly demonstrating that impaired efferocytosis can break immune tolerance.
CD36: bridging oxidised lipoproteins and efferocytosis in atherosclerosis
CD36, a class B scavenger receptor expressed on macrophages, recognises oxidised phosphatidylserine and other oxidised lipid species on apoptotic cell surfaces. In the atherosclerotic plaque — an environment rich in both oxidised LDL (oxLDL) and apoptotic foam cells — CD36-mediated efferocytosis plays a dual role. CD36 can bridge oxLDL-opsonised apoptotic bodies to macrophages, but the same receptor simultaneously internalises oxLDL to generate more foam cells. The balance between efferocytosis and oxLDL uptake via CD36 in plaques is context-dependent, but defective efferocytosis is consistently observed in advanced plaques and correlates with larger necrotic cores and increased plaque vulnerability.
CD47: the "don't eat me" brake
Efferocytosis is not simply activated by eat-me signals; it must also overcome inhibitory "don't eat me" signals on living, healthy cells. The principal such signal is CD47, a broadly expressed cell-surface protein that engages SIRPα (signal regulatory protein alpha) on macrophages. CD47–SIRPα ligation triggers ITIM (immunoreceptor tyrosine-based inhibitory motif) phosphorylation in SIRPα, recruiting SHP-1 and SHP-2 phosphatases that dephosphorylate and thus inactivate the phagocytic machinery. Healthy cells constitutively express CD47 to protect themselves from inadvertent clearance.
Apoptotic cells downregulate CD47 expression as part of their programme, tilting the balance toward recognition. Cancer cells exploit this system in the opposite direction, upregulating CD47 to evade macrophage clearance — a discovery that has driven anti-CD47 therapeutic antibody development (magrolimab/Hu5F9-G4 has entered Phase III trials for AML and myelodysplastic syndrome). The CD47 story elegantly illustrates how efferocytosis is a regulated, signal-integrated process rather than passive phagocytosis.
Where spirulina connects to efferocytosis biology
Spirulina is not an efferocytosis drug, and no clinical trial has directly measured efferocytic capacity in spirulina-supplemented humans. What can be said honestly is that several of spirulina's established molecular effects converge on pathways that modulate efferocytic efficiency.
Phycocyanin, NF-κB suppression, and the M2 macrophage phenotype
Efferocytosis is most efficiently performed by alternatively activated (M2-like) macrophages. Classically activated (M1) macrophages, driven by NF-κB-dependent TNF-α, IL-1β, and IL-6 production, have impaired efferocytic capacity — partly because pro-inflammatory signalling downregulates MERTK surface expression through metalloprotease-mediated ectodomain shedding. C-phycocyanin from spirulina has been shown in multiple cell culture studies to suppress IKKβ-mediated IκBα phosphorylation and the resulting NF-κB nuclear translocation. By reducing the NF-κB-driven inflammatory tone of macrophages, phycocyanin may help preserve the surface availability of MERTK and AXL that M1 polarisation erodes.
AMPK activation and phagosomal processing
Successful efferocytosis does not end at engulfment. The phagosome containing the apoptotic cargo must fuse with lysosomes, and the resulting contents must be degraded and metabolised. This downstream processing depends on functional autophagy machinery — specifically, LC3-II decoration of phagosomes (LC3-associated phagocytosis, LAP), which accelerates phagosome–lysosome fusion and enhances killing capacity. AMPK activation by spirulina compounds, particularly through the AMPK→ULK1→Beclin-1 axis, promotes autophagy initiation. This means that the same AMPK-activating properties that support mitochondrial health and metabolic flexibility may also enhance the post-engulfment processing capacity of macrophages engaged in efferocytosis.
Protecting against oxLDL generation
Spirulina consistently reduces lipid peroxidation markers (malondialdehyde, thiobarbituric acid reactive substances) in human trials, and some studies report modest reductions in LDL oxidation. Since oxLDL-modified apoptotic cell surfaces are a primary ligand for CD36 in atherosclerotic plaques, reducing the oxidative modification of lipids in the plaque microenvironment may shift CD36 engagement away from foam cell formation and toward productive efferocytosis. This is speculative extrapolation from mechanistic endpoints, but it is mechanistically coherent.
What spirulina cannot do
Spirulina has no known direct interaction with AXL or MERTK kinase domains, does not affect Gas6 or Protein S levels in any published dataset, and cannot substitute for the cell-biology determinants of efferocytosis — PS externalisation, CD47 downregulation, and phagocyte cytoskeletal competence — that depend on the apoptotic and phagocytic cells themselves. The connections described above are indirect and largely inferential from mechanistic intermediates. Readers should treat them as plausible hypotheses worth formal testing, not established effects.